- Osu03012
-
- $31.00 / 2mg
-
2026-01-22
- CAS:742112-33-0
- Min. Order:
- Purity: 97.95%
- Supply Ability: 10g
- OSU-03012
-
- $2.00 / 1kg
-
2019-07-06
- CAS:742112-33-0
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100kg
|
| | OSU-03012 Basic information |
| | OSU-03012 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | ≥23 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH | | form | solid | | color | White to off-white | | CAS DataBase Reference | 742112-33-0 |
| | OSU-03012 Usage And Synthesis |
| Description | Cyclooxygenase-2 (COX-2) appears to play a significant role in the development and progression of cancer and COX-2 inhibitors such as celecoxib exhibit anti-cancer activity. OSU03012 is an analog of celecoxib that exhibits anti-cancer activity in a COX-2-independent manner via inhibition of the phosphatidyl inositol-3-kinase/Akt pathway. It has an IC50 value of 5 μM for inhibition of 3-phosphoinositide-dependent kinase-1, and therefore Akt activation, with no measurable COX-2 inhibition up to 50 μM. OSU03012 is a potent inhibitor of tumor cell growth with an average inhibitory concentration of 1.1 μM across a panel of 60 cancer cell lines. It does not inhibit signal transduction through the mitogen-activated protein kinase (MAPK) pathway. OSU03012 induces apoptosis of chronic lymphocytic leukemia cells independent of bcl-2 overexpression using both caspase-dependent and independent pathways. | | Uses | OSU 03012 is a PDK1 inhibitor and inducer of caspase and p53-independent apoptosis, also used in the development of anticancer agents by modification of novel immunosuppressant FTY720 and PDK1 inhibitor OSU-03012, compound for treating Alzheimers diseases. | | Definition | ChEBI: A member of the class of pyrazoles that is N-[4-(pyrazol-1-yl)phenyl]glycinamide in which the pyrazole ring is substituted at positions 3 and 5 by trifluoromethyl and phenanthrene-2-yl groups respectively. | | storage | Store at -20°C | | references | [1] zhu j1, huang jw, tseng ph, yang yt, fowble j, shiau cw, shaw yj, kulp sk, chen cs. from the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. cancer res. 2004 jun 15;64(12):4309-18.
[2] lee tx1, packer md, huang j, akhmametyeva em, kulp sk, chen cs, giovannini m, jacob a, welling db, chang ls. growth inhibitory and anti-tumour activities of osu-03012, a novel pdk-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. eur j cancer. 2009 jun;45(9):1709-20. |
| | OSU-03012 Preparation Products And Raw materials |
|